Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-08 10:03 am Sale | 2023-12-29 | 13G | Verona Pharma plc VRNA | WELLINGTON MANAGEMENT GROUP LLP | 30,271,952 4.730% | -8,383,952 (-21.69%) | Filing History |
| 2023-05-16 4:25 pm Sale | 2023-05-15 | 13D | 89bio, Inc. ETNB | ORBIMED ADVISORS LLC | 3,777,778 4.800% | -482,913 (-11.33%) | Filing History |
| 2023-04-25 4:16 pm Sale | 2023-04-18 | 13G | Verona Pharma plc VRNA | Access Industries Holdings LLC | 0 0.000% | -32,946,296 (Position Closed) | Filing History |
| 2023-04-20 5:01 pm Purchase | 2023-04-18 | 13G | Verona Pharma plc VRNA | PERCEPTIVE ADVISORS LLC | 4,462,666 5.600% | 4,462,666 (New Position) | Filing History |
| 2023-02-14 4:45 pm Sale | 2022-12-31 | 13G | Verona Pharma plc VRNA | RA Capital Management, L.P. | 7,691,990 9.990% | -41,086,182 (-84.23%) | Filing History |
| 2023-02-13 5:47 pm Purchase | 2022-12-31 | 13G | Verona Pharma plc VRNA | VIVO VENTURES VII LLC | 23,142,200 3.800% | 23,142,200 (New Position) | Filing History |
| 2023-02-09 3:57 pm Sale | 2023-02-08 | 13G | Verona Pharma plc VRNA | Access Industries Holdings LLC | 32,946,296 5.450% | -18,165,352 (-35.54%) | Filing History |
| 2023-02-06 2:36 pm Purchase | 2022-12-30 | 13G | Verona Pharma plc VRNA | WELLINGTON MANAGEMENT GROUP LLP | 26,770,960 4.430% | 26,770,960 (New Position) | Filing History |
| 2022-12-27 4:25 pm Sale | 2022-12-22 | 13D | 89bio, Inc. ETNB | ORBIMED ADVISORS LLC | 4,260,691 5.600% | -767,483 (-15.26%) | Filing History |
| 2022-09-07 5:28 pm Purchase | 2022-08-15 | 13D | Verona Pharma plc VRNA | Growth Equity Opportunities Fund IV, LLC | 46,447,651 7.900% | 3,809,520 (+8.93%) | Filing History |
| 2022-08-12 2:29 pm Purchase | 2022-08-10 | 13D | 89bio, Inc. ETNB | ORBIMED ADVISORS LLC | 5,028,174 6.900% | 5,028,174 (New Position) | Filing History |
| 2022-08-11 4:54 pm Purchase | 2022-04-29 | 13D | Verona Pharma plc VRNA | Abingworth LLP | 21,313,822 4.400% | 249,600 (+1.18%) | Filing History |
| 2022-08-10 4:57 pm Purchase | 2022-08-09 | 13G | Verona Pharma plc VRNA | Access Industries Holdings LLC | 51,111,648 10.480% | 6,667,200 (+15.00%) | Filing History |
| 2022-02-14 4:11 pm Purchase | 2021-12-31 | 13G | Verona Pharma plc VRNA | RA Capital Management, L.P. | 48,778,172 9.990% | 7,235,168 (+17.42%) | Filing History |
| 2022-02-11 5:20 pm Unchanged | 2021-12-31 | 13G | Verona Pharma plc VRNA | Vivo Ventures VI LLC | 23,493,716 4.900% | 0 (Unchanged) | Filing History |
| 2022-02-04 09:06 am Purchase | 2021-12-31 | 13G | Verona Pharma plc VRNA | WELLINGTON MANAGEMENT GROUP LLP | 38,655,904 8.340% | 38,655,904 (New Position) | Filing History |
| 2021-02-16 4:34 pm Purchase | 2020-12-31 | 13G | Verona Pharma plc VRNA | RA Capital Management, L.P. | 41,543,004 9.990% | 41,543,004 (New Position) | Filing History |
| 2021-02-05 4:38 pm Sale | 2021-02-02 | 13G | Verona Pharma plc VRNA | Novo Holdings A/S | 12,893,250 3.100% | -9,746,417 (-43.05%) | Filing History |
| 2020-10-05 4:47 pm Sale | 2020-09-30 | 13D | Verona Pharma plc VRNA | Novo Holdings A/S | 22,639,667 5.400% | -408,832 (-1.77%) | Filing History |